Fulcrum Therapeutics, Inc.: 1 tracked 2026 layoff event(s), 0 workers counted, highest AI score 3.
AI score 3 (80% interval 2–4) · evidence grade D · US · Pharma / Chemicals
Stated reason: On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment of sickle cell disease, or SCD. The restructuring plan will reduce Fulcrum’s workforce by approximately 85%, from 57 full-time employees to 9 full-time emplo…
Why 3: Plant, store or site closure · Drivers: contrary evidence −0.8, industry AI exposure +0.5, role AI exposure +0.2
Signals: attribution 0.0, primary 0.0, exec 0.0, role exposure 0.761, industry exposure 0.712, AI investment 0.0, contrary 0.55 · named roles: Computer and Information Systems Managers, General and Operations Managers
Headcount basis: not disclosed
Company AI financials (AI spending, revenue, earnings-call AI mentions) are coming soon to this page.
